71.JPG)
The Nucleic Acid Therapeutics CDMO Market Size is valued at USD 2,272.7 Million in 2023 and is predicted to reach USD 5,293.4 Billion by the year 2031 at an 11.4 % CAGR during the forecast period for 2024-2031.
Key Industry Insights & Findings from the Report:
- A robust pipeline of nucleic acid-based drugs and high levels of investment from pharmaceutical companies and venture capitalists are boosting the market.
- The development of novel nucleic acid-based therapies, such as RNA interference (RNAi), antisense oligonucleotides (ASOs), messenger RNA (mRNA) therapies, and CRISPR-based gene editing, is driving demand for specialized manufacturing services.
- North America dominated the market and accounted for a global revenue share in 2023.
- Scaling up production of nucleic acid therapeutics to meet commercial demand while maintaining quality and cost-effectiveness is a significant challenge.
Nucleic acids are now recognized as the third most crucial platform for drug discovery, following small molecules and antibodies. Through gene inhibition, addition, replacement, or modification, nucleic acid therapeutics implement synthetic oligonucleotides to achieve curative or enduring effects.The science of nucleic acid therapeutics provides promise for treating disorders that cannot be managed with the drugs that are now available.
Nucleic acid therapeutics deal with nucleic acids (DNA and RNA) or other related chemical compounds. The nucleic acid therapeutics CDMO market is estimated to show high growth over the next few years, driven by the high application potential of nucleic acids for a variety of medical conditions. In addition, the increasing preference for personalized medicine also propels the market growth. Furthermore, continued research and development activities for manufacturing innovative nucleic acid therapeutics are forcing pharmaceutical companies to expand their businesses. Most companies focus on partnerships, acquisitions, collaborations, and mergers with contract development and manufacturing organizations (CDMOs) to seamlessly scale oligonucleotides from research to commercial manufacturing. Therefore, scaling up the products cost-effectively and efficiently from research to commercial quantities is a key challenge to CDMOs.
Other driving factors of the nucleic acid therapeutics CDMO market include the growing demand for nucleic acid therapeutics and the high prevalence of chronic and genetic diseases. Furthermore, advancements in nucleic acid technologies, a rise in R&D investments, increasing FDA approvals of nucleic acid therapeutics, and growing CDMO partnerships and acquisitions are expected to escalate the nucleic acid therapeutics CDMO market growth over the forecast years. However, mass production at low cost, lack of expertise in developing nucleic acid therapeutics, and supply chain challenges are anticipated to hinder the industry growth.
Competitive Landscape
Some Major Key Players In The Nucleic Acid Therapeutics CDMO Market:
- Agilent Technologies, Inc.,
- Ajinomoto Co. Inc.,
- Bachem Holding AG.,
- Biospring GmbH,
- Corden Pharma International,
- Danaher Corporation,
- Guangzhou Ruibo Biotechnology Co., Ltd.,
- KNC Laboratories Co., Ltd.,
- LGC Limited,
- Merck KGaA,
- Nippon Shokubai Co., Ltd.,
- Nitto Denko Avecia Inc,
- QIAGEN N.V.,
- ST Pharm Co Ltd,
- Sumitomo Chemical Co., Ltd.,
- Syngene International Limited,
- Thermo Fisher Scientific Inc.,
- Wuxi AppTec,
- Yamasa Corporation,
- Laboratorios Farmacéuticos Rovi, S.A.,
- Sartorius AG (BIA Separations),
- AGC Biologics,
- FUJIFILM Diosynth Biotechnologies,
- Hanmi Pharmaceutical,
- Arranta Bio (Recipharm),
- ST Pharm,
- BioCina Pty Ltd.,
- Curia Global, Inc.
Market Segmentation
The nucleic acid therapeutics CDMO market is segmented by technology (Column-Based Method and Microarray-Based Method), products (Standard Nucleic Acid, Micro-Scale Nucleic Acid, Large-Scale Nucleic Acid, Custom Nucleic Acid, Modified Nucleic Acid, Primers, Probes, Other Nucleic Acid, and Other Services), end-users (Pharmaceutical Companies, Academic Research Institute, Diagnostic Laboratories), and geography (North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa). North America holds the highest share of this market.
Recent Developments:
- In Jan 2023, Agilent Technologies Inc. announced a $725 million investment to manufacture therapeutic nucleic acids as demand for their active pharmaceutical ingredients (API) grows. The small DNA and RNA molecules employed in APIs for a range of diseases are also known as therapeutic oligonucleotides or oligos.
- In Oct 2022, Bachem collaborated with Eli Lilly and Company to develop and manufacture oligonucleotide-based active medicinal components. Bachem offered engineering infrastructure and experience to execute Lilly's new oligonucleotide production technology under the arrangement. Bachem's R&D and production staff in Bubendorf, Switzerland, developed and manufactured GMP-grade material for Lilly's oligonucleotide-based experimental medicines using Lilly's technology.
Nucleic Acid Therapeutics CDMO Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 2,272.7 Million |
|
Revenue Forecast In 2031 |
USD 5,293.4 Million |
|
Growth Rate CAGR |
CAGR of 11.4 % from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Billion and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Product, Technology, End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Agilent Technologies, Inc., Ajinomoto Co. Inc., Bachem Holding AG., Biospring GmbH, Corden Pharma International, Danaher Corporation, Guangzhou Ruibo Biotechnology Co., Ltd., KNC Laboratories Co., Ltd., LGC Limited, Merck KGaA, Nippon Shokubai Co., Ltd., Nitto Denko Avecia Inc, QIAGEN N.V., ST Pharm Co Ltd, Sumitomo Chemical Co., Ltd., Syngene International Limited, Thermo Fisher Scientific Inc., Wuxi AppTec, Yamasa Corporation, Laboratorios Farmacéuticos Rovi, S.A., Sartorius AG (BIA Separations), AGC Biologics, FUJIFILM Diosynth Biotechnologies, Hanmi Pharmaceutical, Arranta Bio (Recipharm), ST Pharm, BioCina Pty Ltd., Curia Global, Inc. and Other Prominent Players. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
